Mumbai, 27 January 2025: The unaudited financial statements for the Q3FY25 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in […]
The post Supriya Lifescience Reports 125% YoY Surge in Q3FY25 PAT to ₹46.78 Crore first appeared on Business News Week.